Celldex Therapeutics, Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Celldex is a clinical-stage biopharmaceutical company developing antibody therapies; it reported no product revenue.
Financial position and results
- Liquidity: Cash, cash equivalents and marketable securities totaled $356.8 million at June 30, 2022, down from $408.3 million at December 31, 2021. Current assets were $368.0 million and current liabilities $29.9 million.
- Cash flow: Net cash used in operating activities was $46.8 million for the first half, versus $30.0 million in the comparable 2021 period. Cash and cash equivalents ended the period at $28.4 million. Investing activities provided $35.7 million, mainly reflecting net maturities and sales of marketable securities.
- Revenue: Q2 revenue was $0.2 million, down from $3.5 million; first-half revenue was $0.3 million, down from $4.2 million. The decline primarily reflected fewer services under manufacturing and research agreements.
- Loss and expenses: Q2 net loss was $36.0 million, or $0.77 per share, compared with $13.4 million, or $0.34 per share. First-half net loss was $59.1 million, or $1.26 per share, versus $29.9 million, or $0.76 per share. First-half R&D expense rose 51% to $37.8 million; G&A rose 67% to $14.1 million. A $15.0 million settlement charge contributed to the higher loss.
- Margins and debt: Operating margins are not meaningful given minimal revenue and continuing development costs. The filing reports no borrowings; liabilities principally include operating leases, accrued expenses and settlement obligations.
Changes, outlook and material items
- Management said cash and investments were sufficient to fund planned operations through 2025, while also noting that future SRS settlement milestones, if paid in cash, could affect that outlook. The filing elsewhere states resources are expected to cover at least the next 12 months.
- Management expects operating cash use to increase over the next 12 months as barzolvolimab development expands. Product-development and personnel expenses are expected to rise; G&A is expected to decline with lower legal expenses. No formal revenue or earnings guidance was provided.
- Barzolvolimab development advanced: Phase 2 studies in chronic spontaneous urticaria and chronic inducible urticaria began dosing in 2022; a Phase 2 EoE study was planned by year-end 2022. The filing describes positive interim CSU Phase 1b results, which are early clinical data and not proof of efficacy in larger studies.
- Celldex and SRS settled the Kolltan milestone litigation. The $15.0 million initial payment was accrued at June 30 and paid after quarter-end upon execution of the definitive agreement in July. The settlement replaced prior potential milestones of up to $172.5 million with a $15.0 million Phase 2 milestone for CDX-0159, subject to a $2.5 million credit, and a $52.5 million milestone upon first FDA or EMA approval of a qualifying product. Future payments may be made in cash, stock or a combination.
- A $6.9 million first-half gain from remeasurement of contingent consideration primarily reflected deprioritization of CDX-1140; Celldex said it would not advance further company-sponsored CDX-1140 studies at that time. The gain partially offset operating costs and is not recurring operating revenue.
- Risks include clinical-trial failure or delay, regulatory uncertainty, rising development costs, reliance on external research/manufacturing providers, COVID-19 disruptions, and the possibility that future financing may be unavailable or dilutive. The company disclosed no material change to previously reported risk factors.
Investor facts to verify
- Reconcile management’s stated runway through 2025 with the separate at-least-12-month liquidity statement and assess the effect of potential settlement payments.
- Track cash burn, clinical and manufacturing spending, and whether expected increases in barzolvolimab costs remain within available resources.
- Review subsequent clinical data and trial progress for barzolvolimab, particularly the Phase 2 urticaria studies and planned EoE study.
- Confirm settlement milestone definitions, payment triggers and the cash-versus-stock election if milestones are achieved.
- Assess the impact of lower contract revenue, stock-based compensation and potential future equity issuance on operating performance and dilution.